1. Home
  2. ATNM vs SACH Comparison

ATNM vs SACH Comparison

Compare ATNM & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.43

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.12

Market Cap

52.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
SACH
Founded
2000
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
52.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ATNM
SACH
Price
$1.43
$1.12
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$4.00
$2.00
AVG Volume (30 Days)
204.3K
181.0K
Earning Date
11-14-2025
11-05-2025
Dividend Yield
N/A
18.35%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$3,906,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$42,943.57
$1.73
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$1.03
$0.80
52 Week High
$2.41
$1.48

Technical Indicators

Market Signals
Indicator
ATNM
SACH
Relative Strength Index (RSI) 51.94 61.68
Support Level $1.40 $1.00
Resistance Level $1.54 $1.14
Average True Range (ATR) 0.09 0.05
MACD 0.02 0.01
Stochastic Oscillator 60.34 85.72

Price Performance

Historical Comparison
ATNM
SACH

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

Share on Social Networks: